Back

dr. W.A.M. (Willeke) Blokx

dr. W.A.M. (Willeke) Blokx

Assistant Professor - medical

Show full profile

Research Output (94)

Ambiguous melanocytic lesions:A retrospective cohort study of incidence and outcome of melanocytic tumor of uncertain malignant potential (MELTUMP) and superficial atypical melanocytic proliferation of uncertain significance (SAMPUS) in the Netherlands

Vermariën-Wang Jiahe, Doeleman Thom, van Doorn Remco, Mooyaart Antien L, Blokx Willeke A M, Schrader Anne M R 17 Nov 2022, In: Journal of the American Academy of Dermatology. 88 , p. 602-608 7 p.

ASO Visual Abstract:Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Blankenstein Stephanie A, Bonenkamp Johannes J, Aarts Maureen J B, van den Berkmortel Franchette W P J, Blank Christian U, Blokx Willeke A M, Boers-Sonderen Marye J, van den Eertwegh Alfons J M, Franken Margreet G, de Groot Jan Willem B, Haanen John B A G, Hospers Geke A P, Kapiteijn Ellen W, van Not Olivier J, Piersma Djura, van Rijn Rozemarijn S, Suijkerbuijk Karijn P M, van der Veldt Astrid A M, Vreugdenhil Gerard, Westgeest Hans M, Wouters Michel W J M, van Akkooi Alexander C J 1 Nov 2022, In: Annals of Surgical Oncology. 30 , p. 587-588 2 p.

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma

van Not Olivier J, Verheijden Rik J, van den Eertwegh Alfonsus J M, Haanen John B A G, Aarts Maureen J B, van den Berkmortel Franchette W P J, Blank Christian U, Boers-Sonderen Marye J, de Groot Jan-Willem B, Hospers Geke A P, Kamphuis Anna M, Kapiteijn Ellen, May Anne M, de Meza Melissa M, Piersma Djura, van Rijn Rozemarijn, Stevense-den Boer Marion A, van der Veldt Astrid A M, Vreugdenhil Gerard, Blokx Willeke A M, Wouters Michel J M, Suijkerbuijk Karijn P M 27 Oct 2022, In: JAMA Oncology. 8 , p. 1794-1801 8 p.

Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Blankenstein Stephanie A, Bonenkamp Johannes J, Aarts Maureen J B, van den Berkmortel Franchette W P J, Blank Christian U, Blokx Willeke A M, Boers-Sonderen Marye J, van den Eertwegh Alfons J M, Franken Margreet G, de Groot Jan Willem B, Haanen John B A G, Hospers Geke A P, Kapiteijn Ellen W, van Not Olivier J, Piersma Djura, van Rijn Rozemarijn S, Suijkerbuijk Karijn P M, van der Veldt Astrid A M, Vreugdenhil Gerard, Westgeest Hans M, Wouters Michel W J M, van Akkooi Alexander C J 6 Oct 2022, In: Annals of Surgical Oncology. 30 , p. 573-586 14 p.

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma

van Not Olivier J, Blokx Willeke A M, van den Eertwegh Alfons J M, de Meza Melissa M, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, de Groot Jan Willem B, Hospers Geke A P, Kapiteijn Ellen, Piersma Djura, van Rijn Rozemarijn S, Stevense-den Boer Marion, van der Veldt Astrid A M, Boers-Sonderen Marye J, Jansen Anne M L, Wouters Michel W J M, Suijkerbuijk Karijn P M Sep 2022, In: JCO Precision Oncology. 6

Response to immune checkpoint inhibitors in acral melanoma:A nationwide cohort study

van Not Olivier J, de Meza Melissa M, van den Eertwegh Alfons J M, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, van Breeschoten Jesper, de Groot Jan-Willem B, Hospers Geke A P, Ismail Rawa K, Kapiteijn Ellen, Piersma Djura, van Rijn Roos S, Stevense-den Boer Marion A M, van der Veldt Astrid A M, Vreugdenhil Gerard, Bonenkamp Han J, Boers-Sonderen Marye J, Blokx Willeke A M, Wouters Michel W J M, Suijkerbuijk Karijn P M 4 Apr 2022, In: European Journal of Cancer. 167 , p. 70-80 11 p.

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients:a propensity-matched survival analysis

van Breeschoten Jesper, Wouters Michel W J M, Hilarius Doranne L, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, de Groot Jan-Willem B, Hospers Geke A P, Kapiteijn Ellen, Piersma Djura, van Rijn Roos S, Suijkerbuijk Karijn P M, Blokx Willeke A M, Tije Bert-Jan J Ten, Veldt Astrid A M van der, Vreugdenhil Art, Boers-Sonderen Marye J, van den Eertwegh Alfonsus J M 7 Mar 2022, In: British Journal of Cancer. 126 1 p.

The unfavorable effects of COVID-19 on Dutch advanced melanoma care

Van Not Olivier J, van Breeschoten Jesper, van den Eertwegh Alfonsus J M, Hilarius Doranne L, De Meza Melissa M, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, de Groot Jan Willem B, Hospers Geke A P, Ismail Rawa K, Kapiteijn Ellen, Piersma Djura, van Rijn Rozemarijn S, Stevense-den Boer Marion A M, van der Veldt Astrid A M, Vreugdenhil Gerard, Boers-Sonderen Marye J, Blokx Willeke A M, Suijkerbuijk Karijn P M, Wouters Michel W J M 1 Mar 2022, In: International Journal of Cancer. 150 , p. 816-824 9 p.

Towards diagnostic criteria for malignant deep penetrating melanocytic tumors using single nucleotide polymorphism array and next-generation sequencing

Ebbelaar Chiel F, Schrader Anne M R, van Dijk Marijke, Meijers Ruud W J, de Leng Wendy W J, Bloem Lourens T, Jansen Anne M L, Blokx Willeke A M, 19 Feb 2022, In: Modern Pathology. 35 , p. 1110-1120 11 p.

Atypical fibroxanthoma and pleomorphic dermal sarcoma:Is superficial infiltration in subcutaneous tissue acceptable in AFX?

van Midden Dominique, Flucke Uta E, Amir Avital L, Bonenkamp Johannes J, Lubeek Satish F K, Blokx Willeke A M 10 Feb 2022, In: Annals of Diagnostic Pathology. 58 , p. 1-7

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not